Lung Cancer News and Research

Latest Lung Cancer News and Research

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

Study reveals potential health risks associated with burning of incense in indoor environments

The burning of incense might need to come with a health warning. This follows the first study evaluating the health risks associated with its indoor use. The effects of incense and cigarette smoke were also compared, and made for some surprising results. The research was led by Rong Zhou of the South China University of Technology and the China Tobacco Guangdong Industrial Company in China, and is published in Springer's journal Environmental Chemistry Letters.

25 Aug 2015

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.

25 Aug 2015

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares.

24 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

Failure To Rescue After Complications Defines Lung Cancer Resection Survival

The variation in mortality rates among patients undergoing lung cancer resection in US hospitals has been attributed by a cohort study to differences in failure-to-rescue rates after the development of complications.

20 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Despite decades of warnings about smoking, lung cancer is still the second-most common cancer and the leading cause of death from cancer in the U.S. Patients are often diagnosed only when their disease is already at an advanced stage and hard to treat. Researchers at the West Coast Metabolomics Center at UC Davis are trying to change that, by identifying biomarkers that could be the basis of early tests for lung cancer.

19 Aug 2015

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant.

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.

14 Aug 2015

IASLC announces winners of Advocacy Travel Awards

The International Association for the Study of Lung Cancer announced today the recipients of the Advocacy Travel Awards. Five winners will receive funding to attend the 16th World Conference on Lung Cancer (WCLC) Sept. 6-9, 2015 at the Colorado Convention Center in Denver.

13 Aug 2015

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.

11 Aug 2015

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead academic centers participating in the National Cancer Institute's (NCI) MATCH (Molecular Analysis for Therapy Choice) Trial in the United States, set to begin in the next few weeks.

11 Aug 2015

WPI awarded NIH grant to explore ways to turn genetic tables against cancer

Taking aim at the fundamental biology of cancer cells, the National Institutes of Health has awarded $747,000 to Worcester Polytechnic Institute for a three-year research project to explore the molecular mechanisms associated with the genetic mutations and chromosome instability observed in all cancer cells.

7 Aug 2015

Cancer survival in England remains lower compared to other countries with similar healthcare systems

Cancer survival in England remains lower than countries with similar healthcare systems, according to a new Cancer Research UK funded study published in the British Journal of Cancer today (Wednesday).

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Study reveals potential health risks associated with burning of incense in indoor environments

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Failure To Rescue After Complications Defines Lung Cancer Resection Survival

DelMar closes on $2.6 million registered direct placement

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Benitec prices initial public offering of 1,500,000 American Depositary Shares

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

Researchers develop new way to personalize treatments for aggressive bladder cancer

IASLC announces winners of Advocacy Travel Awards

Sorrento, TNK Therapeutics to exclusively license NanoVelcro CTC assay from CytoLumina and FetoLumina

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

WPI awarded NIH grant to explore ways to turn genetic tables against cancer

Cancer survival in England remains lower compared to other countries with similar healthcare systems

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in